INTRODUCTION
Several studies have reported associations between donorrecipient sex incompatibility and outcomes following allogeneic hematopoietic SCT (allo-HSCT). 1, 2 In the setting of sex-mismatched allo-HSCT, male-specific mHA (H-Y) encoded by Y chromosome genes could be immunological targets for allogeneic female T cells and B cells to induce GVHD, GVL effect and graft failure. However, most of these studies analyzed patients receiving HLA-compatible transplants using BM or mobilized peripheral blood as a stem cell source for allo-HSCT. [3] [4] [5] [6] [7] [8] Cord blood transplantation (CBT) from an unrelated donor has recently been utilized as an alternative transplant method for adult patients without HLA-compatible, related or unrelated donors. [9] [10] [11] [12] [13] As the majority of patients receive an HLAmismatched cord blood unit, the impact of HLA mismatch on the outcome in CBT has been analyzed extensively. [14] [15] [16] [17] [18] [19] However, there have been no reports detailing the effect of sex incompatibility on the outcomes after CBT. In this study, we retrospectively analyzed whether donor-recipient sex incompatibility affects the outcomes of myeloablative CBT in 191 adult patients with hematological malignancies in our institute.
PATIENTS AND METHODS

Patients and transplant procedures
This retrospective study included data from 191 adult patients who underwent unrelated first allogeneic transplantation using single-unit CBT at The Institute of Medical Science, The University of Tokyo, between August 1998 and February 2013. Donor-recipient sex compatibility was categorized as follows: CBT from female donor to female recipient (F-F), CBT from female donor to male recipient (F-M), CBT from male donor to female recipient (M-F) and CBT from male donor to male recipient (M-M). All patients received 12 Gy TBI-based myeloablative conditioning regimens and cyclosporin (3 mg/kg/day) with or without short-term MTX (15 mg/m 2 on day 1 and 10 mg/m 2 on days 3 and 6) as a GVHD prophylaxis, and cord blood units were selected as previously reported. 12, 13 The institutional review board of the Institute of Medical Science, The University of Tokyo approved this study. This study was conducted in accordance with the declaration of Helsinki.
End points and statistical analysis
The primary study end point was GVHD. Both acute GVHD (aGVHD) and chronic GVHD (cGVHD) were graded according to the previously published criteria. 20, 21 The incidence of aGVHD was evaluated in all engrafted patients, whereas the incidence of cGVHD was evaluated in engrafted patients surviving for 4100 days. Secondary end points were OS, relapse, TRM, and neutrophil and platelet engraftment. OS was defined as the time from the date of transplantation to the date of death or last contact. Relapse was defined by morphologic evidence of disease in peripheral blood, BM or extramedullary sites. TRM was defined as death during a remission. Neutrophil engraftment was defined as the first of three consecutive days during which the absolute neutrophil count was at least 0.5 Â 10 9 /L. Platelet engraftment was defined as the first of seven consecutive days with a platelet count of 20 Â 10 9 /L or higher without platelet transfusion.
Baseline patient and transplant characteristics were compared using the chi-square test for categorical variables and the Kruskal-Wallis test for continuous variables. The probability of OS was estimated according to the Kaplan-Meier method, and the groups were compared using the log-rank test. The probabilities of the others were estimated on the basis of a cumulative incidence method to accommodate competing risks. 22 Multivariate analysis was performed with a Cox proportional hazard model adjusted for OS, and a Fine and Gray proportional hazards model for the others. 23 The following variables were considered: age (o45 vs X45 years), CMV serostatus (negative vs positive), disease status at CBT (standard risk vs high risk), cord blood CD34 þ cell count (o1 Â 10 5 vs X1 Â 10 5 /kg), cord blood nucleated cell count (o2.5 Â 10 7 vs X2.5 Â 10 7 / kg), HLA disparities (p2 vs X3) and donor-recipient sex compatibility (F-F vs F-M vs M-F vs M-M). In this study, the F-F group was considered the reference group in the multivariate analyses, because this group is not influenced by H-Y Ags. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R 2.13.0 (R Foundation for Statistical Computing, Vienna, Austria). 24 Po0.05 was considered significant. Analysis of data was performed in August 2013.
RESULTS
Patients
The characteristics of patients and cord blood units are shown in Table 1 . There were no significant differences among the four sex combination groups, except for cord blood nucleated cell counts ( Table 1 ). The median period of follow-up for survivors after CBT was 92 months (range, 5-181 months).
GVHD CBT in the F-M group had a theoretical increased risk of both aGVHD and cGVHD, because H-Y Ags can be targets for donor T cells and B cells. In univariate analysis, there was no significant difference in the cumulative incidence of grade II-IV aGVHD among the four groups ( Figure 1a) . In multivariate analysis, a lower cord blood CD34 þ cell count (hazard ratio (HR), 0.66; 95% confidence interval (CI), 0.46-0.94; P ¼ 0.02) and high risk of disease status at CBT (HR, 0.69; 95% CI, 0.48-0.98; P ¼ 0.04) were associated with a lower incidence of grade II-IV aGVHD. Nevertheless, the incidence of grade II-IV aGVHD was similar for the F-M group, M-F group and M-M group compared with the F-F group (Table 2 ). In addition, there was no significant difference in the cumulative incidence of grade III-IV aGVHD among the four groups (P ¼ 0.34) ( Table 2 ). In univariate analysis, there was no significant difference in the cumulative incidence of extensive cGVHD among the four groups (P ¼ 0.11) (Figure 1b ). Multivariate analysis indicated that the F-M group was a significant risk factor for extensive cGVHD compared with the F-F group (HR, 2.97; 95% CI, 1.14-7.69; P ¼ 0.02) ( Table 2 ).
OS, relapse and TRM The probability of OS at 7 years did not differ significantly among the four groups in univariate analysis (P ¼ 0.32) (Figure 1c) and Table 1 . Characteristics of patients, cord blood units and transplantation Disease status at CBT was classified as standard risk or high risk; CR1 or CR2 without poor prognostic karyotype for AML and ALL, refractory anemia for MDS, chronic phase for CML, and CR1 or CR2 for NHL were classified as standard risk, whereas patients in all other situations were classified as high risk. The number of HLA disparities defined as low resolution for HLA-A and -B and high resolution for HLA-DRB1.
Sex incompatibility in CBT T Konuma et al multivariate analysis (Table 2) . We also analyzed a subgroup of patients with standard risk or high risk of disease status at CBT. However, we were unable to find any impact of sex incompatibility on survival relating to disease risk at CBT (data not shown). Sex incompatibility was not associated with cumulative incidence of relapse (Table 2) . A trend toward a higher incidence of TRM was observed in the F-M group compared with the F-F group, but this was not significant in univariate analysis (P ¼ 0.09) (Figure 1d ) or multivariate analysis (P ¼ 0.07) ( Table 2) .
Engraftment
Female recipients with male donors have a theoretical increased risk of graft rejection, because the H-Y Ags can be a target for recipient T cells and B cells. In univariate analysis, there was no significant difference in the cumulative incidence of neutrophil engraftment among the four groups (Figure 1e) . In multivariate analysis, a lower cord blood CD34 þ cell count (HR, 0.51; 95% CI, 0.37-0.70; Po0.001) and high risk of disease status at CBT (HR, 0.68; 95% CI, 0.51-0.93; P ¼ 0.01) were associated with a lower incidence of neutrophil engraftment, but sex incompatibility was not associated with neutrophil engraftment (Table 2) . In univariate analysis, the cumulative incidence of platelet recovery was not significantly different among the four groups (Figure 1f) . In multivariate analysis, the M-F group showed a significantly lower incidence of platelet engraftment when compared with the F-F group (HR, 0.56; 95% Cl, 0.34-0.091; P ¼ 0.02) ( Table 2 ). In addition, a lower cord blood CD34 þ cell count (HR, 0.58; 95% CI, 0.42-0.80; Po0.01), positive CMV serostatus (HR, 0.48; 95% CI, 0.32-0.74; Po0.001) and high risk of disease status at CBT (HR, 0.57; 95% CI, 0.41-0.78; Po0.001) were associated with a lower incidence of platelet engraftment.
DISCUSSION
We examined the effects of donor-recipient sex incompatibility on the outcome of CBT in our institute. The effect of sex incompatibility on transplant outcome might differ depending on the kinds of stem cell sources in allo-HSCT. Gallardo et al. 6 demonstrated the association of a sex-mismatch and grade III-IV aGVHD, higher TRM and lower OS in HLA-compatible BMT, but not HLA-compatible PBSC transplantation. In addition, Sterm et al. 25 reported the largest retrospective study for evaluating the effect of sex incompatibility in 53 988 allogeneic transplants using Sex incompatibility in CBT T Konuma et al various hematopoietic stem cell sources. As only 734 (1.3%) patients received CBT among the 53 988 patients, the details of CBT outcomes were not described. In the CBT setting, the sex of recipients has become a confounding factor for outcome. 26, 27 Although sex incompatibility was considered as a factor influencing the outcome in several CBT studies, [14] [15] [16] 28, 29 there have been no reports detailing the effect of sex incompatibility on outcomes after CBT. Our results showed a higher risk of extensive cGVHD in the F-M group and a lower incidence of platelet engraftment in the M-F group compared with the F-F group in the multivariate analysis. These effects might be associated with allogeneic immune responses against H-Y Ags. However, there were no differences in OS, TRM and relapse among all four groups.
Male recipients with female donors had an increased incidence of GVHD, particularly cGVHD, [3] [4] [5] [6] [7] 30 which led to a higher TRM and lower OS in the setting of HLA-compatible allo-HSCT. Recently, Newell et al. 31 demonstrated a shorter duration and a higher response of cGVHD to systemic immunosuppressive treatment in CBT recipients than in BMT or PBSC transplantation recipients, which might have contributed to extensive cGVHD not being shown to increase TRM in our study. It has been reported that a decreased risk of relapse is associated with aGVHD and cGVHD in leukemia patients after BMT. 32 In fact, several studies demonstrated that male recipients with female donors had a lower risk of relapse in leukemia and myeloma, [3] [4] [5] suggesting that sex incompatibility may contribute to the GVL effects. However, we were unable to find any impact of sex incompatibility on relapse in the entire cohort and in subgroup analysis on the basis of disease risk at CBT (data not shown). On the other hand, it has been reported that female recipients with male donors had a higher risk of graft failure in aplastic anemia following allo-HSCT. 8 Moreover, the role of H-Y Ags in graft rejection of solid organ transplantations has also been reported extensively, particularly in kidney transplantations. 33, 34 In our study, female recipients with Sex incompatibility in CBT T Konuma et al male donors were significantly associated with a lower incidence of platelet engraftment, but not neutrophil engraftment. Our data showed that the most important factor in neutrophil and platelet engraftment was the cord blood CD34 þ cell count, indicating that this is more important than sex incompatibility in engraftment after CBT.
In HLA-compatible allo-HSCT, GVHD and GVL effects might be induced by allogeneic immune responses against mHA, which can be presented by HLA in normal or leukemia cells. mHA are HLA-restricted polymorphic peptides derived from intracellular proteins encoded by polymorphic genes. H-Y Ags can be recognized by female donor or recipient T cells in the setting of sex-mismatched allo-HSCT. Several H-Y Ags, such as SMCY, DFFRY, UTY, DBY, RPS4Y and TMSB4Y, have been identified and were recognized by either CD4 þ or CD8 þ T cells. 35, 36 It has been reported that male recipients with female donors have a greater risk of cGVHD than aGVHD in allo-HSCT. [3] [4] [5] [6] [7] 30 In addition, the detection of alloantibody and alloantibody-producing B cells against H-Y Ags was associated with cGVHD in sex-mismatched allo-HSCT. 37, 38 In fact, our data also showed that male recipients with female donors were significantly associated with a higher incidence of extensive cGVHD, but not aGVHD. Although the existence of alloantibodies against H-Y Ags was not clarified in our study, specific alloantibodies against H-Y Ags should be investigated in future studies.
In conclusion, our data showed that donor-recipient sex combination affects the incidences of extensive cGVHD and platelet engraftment, but does not have a significant effect on the OS after CBT. However, these results should be interpreted with caution because this retrospective study included a relatively small number of Japanese patients who received single-unit CBT following 12 Gy TBI-based myeloablative conditioning regimens for hematological malignancies. Although these findings should be confirmed in prospective studies, donor-recipient sex combination does not appear to have a significant impact on survival after CBT.
